Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia.

MLA

Jung, Christian B., et al. “Dantrolene Rescues Arrhythmogenic RYR2 Defect in a Patient-Specific Stem Cell Model of Catecholaminergic Polymorphic Ventricular Tachycardia.” EMBO Molecular Medicine, vol. 4, no. 3, Mar. 2012, pp. 180–91. EBSCOhost, https://doi.org/10.1002/emmm.201100194.

APA

Jung, C. B., Moretti, A., Mederos y Schnitzler, M., Iop, L., Storch, U., Bellin, M., Dorn, T., Ruppenthal, S., Pfeiffer, S., Goedel, A., Dirschinger, R. J., Seyfarth, M., Lam, J. T., Sinnecker, D., Gudermann, T., Lipp, P., & Laugwitz, K.-L. (2012). Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia. EMBO Molecular Medicine, 4(3), 180–191. https://doi.org/10.1002/emmm.201100194

Chicago

Jung, Christian B, Alessandra Moretti, Michael Mederos y Schnitzler, Laura Iop, Ursula Storch, Milena Bellin, Tatjana Dorn, et al. 2012. “Dantrolene Rescues Arrhythmogenic RYR2 Defect in a Patient-Specific Stem Cell Model of Catecholaminergic Polymorphic Ventricular Tachycardia.” EMBO Molecular Medicine 4 (3): 180–91. doi:10.1002/emmm.201100194.